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CFTR exon 10 and its ﬂanking regions are duplicated in the human genome. These duplications present mutations compared to the normal exon 10
sequence. Due to the polymorphic sequence of the 3′ intron 9 sequence, it may appear difﬁcult to sequence exon 10 and some mutations described in
this exon could, in fact, be variations observed in an ectopic duplicated sequence.
In our previous work we described a methodology to carry out PCR only of exon 10 and not of ectopic regions. In this work, we analyzed mutations
described in the CF data base as being CFTR mutations but also found in ectopic regions: c.1392GNT, c.1338_1339delAT, c.1235delC, and
c.1247ANG. We have shown that these mutations appear to be authentic mutations in CFTR exon 10 and not ectopic variations in analyzed patients.
These mutations validate the usefulness of our new strategy in the mutation analysis of this region of CFTR.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CFTR exon 10; CFTR pseudomutations; Nucleotide sequence analysis; Human genome1. Introduction
CFTR, the gene that encodes the cystic fibrosis transmembrane
conductance regulator, which is located on chromosome 7, is
responsible for cystic fibrosis (CF). It encodes a large transmem-
brane protein of 1480 amino acids that forms an ATP- and cAMP-
dependent chloride channel found in the apical border of epithelial
cells lining most exocrine glands [1]. The CFTR mutation
databases are useful for screening different populations and are
especially useful to laboratories involved in the diagnosis of
CFTR mutations. The identification and confirmation of new⁎ Corresponding author at: Institut de Physiologie et Biologie Cellulaires
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;lishedmutations in this gene are challenging but important for improving
the diagnosis of this disease, particularly in the CF clinics. To date,
more than 1900 mutations of the CFTR gene have been reported
(Cystic Fibrosis Mutation Database, http://www.genet.sickkids.
on.ca/cftr/, last accessed 04/07/2012), but little is known about the
molecular mechanisms by which these mutations affect the
function of CFTR, and only a minority have been characterized at
the protein level [2]. However, mutational heterogeneity in CFTR
complicates CF diagnosis at the DNA level.
BLAST analysis of CFTR exon 10 in the new nomenclature
(exon 9 in the ancient nomenclature) and its flanking intronic
regions has revealed several repeat sequences of this region in the
human genome [3]. Surprisingly, the c.1392+6insC; c.1392+
12GNA (1524+6insC; 1524+12GNA) mutations were basically
found in all of these pseudogene sequences. Therefore, sequence
homology, structure alignment and the correct identification ofby Elsevier B.V. All rights reserved.
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pseudomutations [4]. Indeed, our previous results suggested that
several mutations described in exon 10 and its flanking regions
may in fact be ectopic variations from sequences detected in
pseudogenes: c.1392GNT (p.Lys464Asn, 1524GNT), c.1338_13
39delAT (p.Ile444X, 1460delAT), c.1235delC (p.Ala412GlufsX
30, 1367delC), and c.1247ANG (p.Asn416Ser, N416S) [4].
Recently, we received DNA samples previously described as
bearing the mutations c.1235delC; c.1247ANG; c.1392GNT in
exon 10, and c.1392+6insC; c.1392+12GNA in intron 10. The
present study aims to identify mutations in the CFTR exon 10.
Here we describe the current use of our method to re-examine
DNA samples from patients carrying such mutations to validate
this approach for precise diagnosis and to avoid future mis-
amplification of duplicated sequences.
1.1. Case report
The c.1235delCmutation was identified in a French CF patient
diagnosed at birth; he had idiopathic pancreatitis (IP) and had
severe lung disease and sweat chloride of 176 mmol/L. He carried
the c.1521_1523delCTT mutation (p.Phe508del, F508del) on the
other allele (Ferec C, personal communication).
The c.1392GNT mutation was identified in one CF patient
carrying the c.3659delC mutation on the other chromosome.
No other mutation was detected after extensive screening for
CFTR mutations (27 exons and intronic boundaries) by
DHPLC methodology. The patient (French origin) was a
newborn child referred for elevated immunoreactive trypsinogen
(newborn screening) and positive sweat test (Cl−N100 mEq/L).
At age 6 months, he expressed a severe phenotype with
pancreatic insufficiency, chronic cough, and bronchial infection
(H. influenzae and S. aureus; Bieth E, personal communication).
The c.1392+6ins C; c.1392+12GNA mutations were identi-
fied in five French patients from independent families. The first
case was a 34-year-old woman initially diagnosed with bronchi-
ectasis with cough and dyspnea without digestive and pancreatic
problems. The second case was a 62-year-old man initially
diagnosed with obstructive pulmonary disorder without digestive
and pancreatic problems. Moreover, no other mutations were
identified in these two patients. The third case was that of a
19-year-old adolescent initially diagnosed with CF. He revealed
the heterozygous presence of c.1521_1523delCTT (p.Phe508del,
F508del) and c.617TNG (p.Leu206Trp, L206W) mutations
(Bienvenue T, personal communication). The two other cases
have been published previously [4].
The c.1247ANG mutation was detected in a 30-year-old man
during the screening program of relatives carriers. It was seen
only once, in over 3000 chromosomes analyzed by DGGE. No
other mutation was found. (Picci L, personal communication).
2. Materials and methods
2.1. CFTR mutation analysis
The mutation detection test was performed on DNA collected
from 8 individuals in 7 different families. The reported cases werereferred to Centre Hospitalier Universitaire de Poitiers (2 cases);
Assistance Publique, Hôpitaux de Paris (3 cases); Hôpital Purpan,
Toulouse (2 cases); and Laboratoire de Génétique Moléculaire,
Brest (1 case), regarding the diagnosis of CF disorder.
Genomic DNA samples were extracted from blood leukocytes
using the QiaAmp DNA Blood Mini kit (Qiagen) according to
protocols provided by the manufacturer. Extensive CFTR gene
analyses were performed in the patients and healthy individuals
using a combination of methods including: (i) screening for
frequent mutations using diverse commercial assays; (ii) scanning
of the 27 exons and their boundaries using denaturing gradient gel
electrophoresis (DGGE) or denaturing high pressure liquid phase
chromatography (DHPLC), followed by sequencing to character-
ize the variants; (iii) screening for largeCFTR rearrangements. The
CFTR mutation analysis was performed for the mutations
c.1235delC, c.1247ANG and c.1392GNT in exon 10 and
c.1392+6insC; c.1392+12GNA in intron 10, respectively by
PCR amplifications (Fig. 1a). The conditions used for
amplification were as follows: 5 min at 94 °C; 30 cycles of
30 s at 94 °C followed by 30 s at annealing temperature and
30 s at 72 °C; and a final extension step for 5 min at 72 °C.
The amplicons were sequenced directly on an ABI Prism 310
Genetic Analyzer using the ABI PRISM™ Big Dye™
Terminator Cycle Sequencing Kit (PE Applied Biosystems)
with targeted primers. Sequencing results were compared with the
sequence of the wild-type CFTR gene published in the Cystic
Fibrosis Mutation Database (http://www.genet.sickkids.on.ca/cftr/
Home.html). The specific primers for the identification of these
mutations were as follows: Forward primer, CF9-184, 5′-CCTCT
AGAAACCGTATGC-3′; and reverse primer, CF9+58, 5′-CCT
TCCAGCACTACAAACTAGAAA-3′. The homologous se-
quences of CFTR exon 10 and its flanking introns analyzed in
this study were obtained from GenBank accession numbers (for
reference, see El-Seedy et al., 2009).
2.2. Mutation nomenclature
Mutations at the protein level were named according to the
recommendations of the Human Genome Variation Society
(HGVS) guidelines (http://www.hgvs.org/mutnomen/). For those
described at the nucleotide level, DNA mutation numbering is
based on the cDNA sequence (GenBank NM_000492.3) that uses
the A of the ATG translation initiation start site as nucleotide +1
[5] and on the CFTR Mutation Database (http://www.genet.
sickkids.on.ca/cftr/). The traditional nomenclature is also included
using nucleotide position 133 as the translational start site.
3. Results and discussion
Molecular diagnosis for CFTR exon 10 mutations is difficult
because this exon and its flanking sequences (especially the
downstream sequences) have been duplicated and inserted into
several chromosomes as pseudogenes [3] and because of the
presence of polymorphic tracts upstream of exon 9. The TG and
poly (T) repeats in intron 9 just upstream of exon 10 can lead to
a reduction of the exon 10 signal [6]. The typical length of the
poly (TG) tract is 10–12 copies, whereas the usual poly (T)
Fig. 1. CFTR exon 10 region and its duplicated sequences in the human genome. (a) Localization of CFTRmutations found in duplicated sequences of exon 10 and its
intronic flanking regions. These variants may be due to the sequence identity with similar sequences in the human genome that markedly increase priming artifacts.
(b) Chromosomal location of CFTR exon 10 on chromosome 7 and the duplicated CFTR exon 10 regions. The positions in these sequences of the previously
described CFTR mutations are shown (arrowheads). The black triangles indicate mutations found in all duplicated sequences and that are not CFTR exon 10
mutations. The black circles indicate location of the CFTR mutations not tested in this study. The black squares show tested and authentic mutations.
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frequency [7,8]. The combination of these polymorphisms and
the multiple pseudo-exon 10 copies on other chromosomes limits
the choice of primers to use for amplification of exon 10. Thus,
the inclusion of confirmatory fragments for exon 10 is necessary
[9].
DNA samples were screened for mutations within CFTR
using primers that hybridize to intron 9 and intron 10 to avoid
interference with other sequences in the human genome. Direct
sequencing of amplified fragments was performed with the
same PCR primers for three new patients from Cochin Saint
Vincent de Paul Hospital and two patients from Poitiers CHU
who had previously been diagnosed as carrying the c.1392+
6insC; c.1392+12GNA mutations in intron 10. The results are
shown in comparison with the sequence of wild-type CFTR.
This finding has been reported previously and confirms that
variants are pesudomutations and are in fact a PCR artifact and
the consequence of the existence of multiple copies of this
region in the human genome. Indeed, these variants are not
found within the CFTR gene, whereas they are present in each
duplicated region (Fig. 1b).
The c.1392GNT, c.1247ANG and c.1235delC mutations
described in this report were identified in the examined patients
by direct sequencing (Fig. 2a-c). Thus, these variants appear to be
authentic mutations in CFTR exon 10. Moreover, they were
observed only in one or two duplicated sequences (Fig. 1b). The
c.1235delC mutation, a frameshift that causes deletion of cytosine
at position 1235, was first described in a French CF patient (Ferec
C, personal communication).
The c.1392GNT mutation is a transversion in exon 10, which
causes a change of Lysine to Asparagine at position 464 of the
CFTR polypeptide. This substitution is predicted to reducesplicing efficiency. The effect of the predicted splicing mutation
c.1392GNT (p.Lys464Asn, K464N) was analyzed by computer-
assisted splice-site prediction using Human Splicing folder
website. This mutation should affect the strength of the splice
site (data not shown). This variant was identified in one patient
with CF carrying the c.3659delC (p.Thr1220LysfsX8, 3791delC)
mutation on the other chromosome, which leads to a frame shift
mutation starting from codon 1220 (Bieth E, personal communi-
cation). Further experiments could be performed to determine the
impact of the c.1392GNT mutation on splicing. The c.1247ANG
(p.Asn416Ser, N416S) mutation is a transition mutation of c.124
7ANG in exon 10 (Fig. 2b), which causes a change in asparagine
to serine at position 416 of the CFTR polypeptide.
Table 1 summarizes the results of each mutant genotype
obtained by direct amplification and sequencing, which confirmed
the presence of different alleles. No published cases of such
genotypes exist. Confirmation of the presence of such mutations
will help to judge the severity of these mutations and the resulting
defective channel formation and how they relate to the course of
CF.
4. Conclusion
In conclusion, we present here the two primers used for the PCR
amplification and sequencing analysis ofCFTR exon 10, which are
very specific for the amplification of this exon. This approach may
be useful in studying and characterizing mutations in this region in
CF patients. Furthermore, our previous study [4] and our new
findings in patients carrying the c.1392GNT and c.1235delC
mutations in exon 10 will help with the genetic evaluation and
screening of patients with these mutations to diagnose CF with
much greater accuracy. These mutations validate the usefulness of
Fig. 2. DNA sequence of exon 10 from the examined patients: c.1392GNT (a),
c.1247ANG (b) and c.1235delC (c) mutations. The black points indicate these
mutations. For the c.1235delC (c) mutations, the deletion induces a frameshift,
visible at the left of the mutation.
Table 1Mutations in CFTR and in the duplicated exon 10 regions.
CFTR mutation
(legacy name)
Amino acid change Site of
mutation a
Status Consequences
c.1235delC
(1367delC)
p.Ala412GlufsX b30 Exon 10 M Frameshift
c.1392GNT
(1524GNT)
p.Lys464Asn Exon 10 M Severe
mutation,
mRNA
splicing defect?
c.1330_1331delAT
(1460delAT)
p.Ile444X Exon 10 ND Frameshift
c.1247ANG
(1379ANG)
p.Asn416Ser Exon 10 M Unknown
c.1392+6ins C;
c.1392+12GNA
(1524+6insC;
1524+12GNA)
Intron 10 NM None
Abbreviations: fs, frameshift; X, change in DNA sequence that causes translation
to stop; M, CFTR real mutation; ND, not determined; NM, no mutation in CFTR
gene.
These mutations were previously reported as personal communications to the CF
Genetic Analysis Consortium (http://www.genet.sickkids.on.ca/cftr, last accessed
10/07/2012).
a Conventional CFTR exon/intron numbering includes exons 6 and 7, exons
15 and 16, and exons 19 and 20; for exon/intron numbers, these exon pairs are
numbered sequentially, without modiﬁers such as “6a” and “6b”.
b Position of deletion of base(s) in DNA sequence which results in shift in the
reading frame during translation.
410 A. El-Seedy et al. / Journal of Cystic Fibrosis 12 (2013) 407–410our new strategy in the mutation analysis of this region of CFTR.
Thus, we suggest that only c.1392+6insC and c.1392+12GNA
mutations, which are found in all duplicated sequences, are not
authentic mutations in CFTR as previously described [4].
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